Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold
Harrow, Inc. has been rated as a Hold following its Q1 2026 performance, which showed execution risks despite strong demand for its products. The company's revenue and adjusted EBITDA fell short of expectations, indicating a need for better revenue conversion and operating leverage. Achieving its 2026 guidance will require significant revenue growth and EBITDA recovery, with the current valuation reflecting an anticipated turnaround.
- ▪Harrow's Q1 2026 revenue and adjusted EBITDA missed expectations.
- ▪The company faces challenges in translating prescription growth into predictable financials.
- ▪Current valuation already factors in the need for a successful turnaround.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906880-harrow-demand-keeps-it-interesting-valuation-keeps-it-a-hold"},"author":{"@type":"Person","name":"High Alpha Professor","url":"https://seekingalpha.com/author/high-alpha-professor"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
